Narumi Nakagiri
Stock Analyst at Daiwa Capital
(0.88)
# 2,832
Out of 4,667 analysts
10
Total ratings
60%
Success rate
-5.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Narumi Nakagiri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ILMN Illumina | Upgrades: Buy | $120 → $154 | $131.68 | +16.95% | 1 | Aug 16, 2024 | |
| PFE Pfizer | Upgrades: Outperform | $28 → $34 | $24.84 | +36.88% | 3 | Aug 8, 2024 | |
| JNJ Johnson & Johnson | Downgrades: Neutral | $160 → $150 | $153.87 | -2.52% | 1 | Jul 23, 2024 | |
| AMGN Amgen | Upgrades: Buy | $320 | $287.87 | +11.16% | 2 | Dec 21, 2023 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $68 → $54 | $58.07 | -7.01% | 1 | Nov 2, 2023 | |
| MRK Merck & Co. | Upgrades: Outperform | $89 → $102 | $97.44 | +4.68% | 2 | Jul 7, 2022 |
Illumina
Aug 16, 2024
Upgrades: Buy
Price Target: $120 → $154
Current: $131.68
Upside: +16.95%
Pfizer
Aug 8, 2024
Upgrades: Outperform
Price Target: $28 → $34
Current: $24.84
Upside: +36.88%
Johnson & Johnson
Jul 23, 2024
Downgrades: Neutral
Price Target: $160 → $150
Current: $153.87
Upside: -2.52%
Amgen
Dec 21, 2023
Upgrades: Buy
Price Target: $320
Current: $287.87
Upside: +11.16%
Bristol-Myers Squibb Company
Nov 2, 2023
Downgrades: Neutral
Price Target: $68 → $54
Current: $58.07
Upside: -7.01%
Merck & Co.
Jul 7, 2022
Upgrades: Outperform
Price Target: $89 → $102
Current: $97.44
Upside: +4.68%